Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Coalition asks for agency leader with industry experience

This article was originally published in The Tan Sheet

Executive Summary

The Department of Health and Human Services secretary-designate should not disqualify FDA commissioner candidates "due to relationships with industry during the course of his/her career," a group of health organizations called the "FDA Commissioner Coalition" in media reports says in a letter to former Sen. Tom Daschle. Experience within "an FDA-regulated industry should be viewed as a positive qualification," as should solid scientific credentials, the ability to build consensus and a commitment to advance evidence-based science in the area of drug development, says the coalition, which includes groups with industry ties. Biotechnology and pharmaceutical stakeholders voiced concern over the Obama administration leaning toward an FDA head hostile to industry (1"The Tan Sheet" Nov. 10, 2008, p. 3). Groups signing the letter include the Alliance for Aging Research, the American Cancer Society and WomenHeart

You may also be interested in...

With Democrat In White House, “More Aggressive” FDA Comes Into Focus

Democratic control of the White House, Senate and House brings the potential of a "more aggressive" FDA into sharp focus

Bio-Thera IPO Raises $241m

Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.

Fewer Wuhan Patients For Gilead Remdesivir Study: WHO

In a shocking and revealing account, a primary investigator of the front-runner antiviral drug for the coronavirus in China expresses concerns over finding enough patients for the study Wuhan, the outbreak's epicenter.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts